Using Antibody Based Drug Therapies to Cure Cancer-The Success Story of Clay Siegall

Cancer has been a scourge that has plagued humanity for quite some time now. It is our nature to be resilient and find solutions, and that is exactly what Dr. Clay Siegall has done. Many companies in the world are working on cancer research. Seattle Genetics has been an industry leader in cancer drug therapy research for almost decade now. Seattle Genetics was founded in 1998. The company was based on firm beliefs of rigorous study and drug development practices. The philosophies, combined with Dr. Siegall passion for helping patients has been the secret behind the company’s success.

Imagine working at a place where you know your job matters or where you know your job can potentially save lives. It is what it feels like to work at Seattle Genetics. The employees are always motivated to push beyond the ordinary. The experience was the driving force behind the development of the antibody-drug conjugates (ADCs). Seattle Genetics secured approval from the FDA in 2011 for the first ADC product. ADCETIRIS is the company’s flagship ADC drug and has been approved in more than 65 countries. In a strategic partnership move with Takeda Pharmaceutical Company ADCETRIS is now a global brand.

With Dr. Siegall at the helm, Seattle Genetics has entered into several strategic licenses for the ADC technology with companies like Genentech, GlaxoSmithKline, Pfizer, and AbbVie. These licenses have generated the company $350 million. With more than 20 ADCs in clinical development through internal and collaborative programs, the company’s revenue can only go up. Dr. Siegall has made significant strides in his role as CEO. Although a scientist by training, his business know-how has been unquestionable. He has led Seattle Genetics to raise capital through public and private financing. Managing to raise more than $1.2 billion the company is now worth more than $9 billion.

Siegall is a Ph.D. holder from George Washington University. He also boasts a B.S in Zoology from the University of Maryland. He has widely published as an author of medical journals and articles. Clay has also bagged some rewards as an entrepreneur. He recently won the prestigious Pacific Northwest Ernst&Young Entrepreneur of the Year award. His dream is to advance research into ADC technology and help modern-day cancer patients achieve an excellent outcome.

Leave a Reply

Your email address will not be published. Required fields are marked *